NMRA
NASDAQ
$1.63
Neumora Therapeutics Inc (NMRA)
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company is headquartered in Watertown, Massachusetts.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6.28 (+285.28%)
Market Cap
$293M
Free Cash Flow Yield
-65.97%
Beta (5Y)
1.20
Price Chart
Valuation
Market Cap$293M
P/B4.14
Profitability
EBITDA-$223M
EPS-$1.40
Financial Health
Debt-to-Equity159.8%
Free Cash Flow Yield-65.97%
Growth & Risk
Beta (5Y)1.20
Sharpe Ratio0.55